JP5922018B2 - Ｍｕｃ１抗体 - Google Patents

Ｍｕｃ１抗体 Download PDF

Info

Publication number
JP5922018B2
JP5922018B2 JP2012522029A JP2012522029A JP5922018B2 JP 5922018 B2 JP5922018 B2 JP 5922018B2 JP 2012522029 A JP2012522029 A JP 2012522029A JP 2012522029 A JP2012522029 A JP 2012522029A JP 5922018 B2 JP5922018 B2 JP 5922018B2
Authority
JP
Japan
Prior art keywords
antibody
fragment
cancer
derivative
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012522029A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013500703A (ja
JP2013500703A5 (enExample
Inventor
シュテファン ゴレツ，
シュテファン ゴレツ，
アンチェ ダニエルチク，
アンチェ ダニエルチク，
レナテ シュタン，
レナテ シュタン，
ウヴェ カルステン，
ウヴェ カルステン，
Original Assignee
グリコトープ ゲーエムベーハー
グリコトープ ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グリコトープ ゲーエムベーハー, グリコトープ ゲーエムベーハー filed Critical グリコトープ ゲーエムベーハー
Publication of JP2013500703A publication Critical patent/JP2013500703A/ja
Publication of JP2013500703A5 publication Critical patent/JP2013500703A5/ja
Application granted granted Critical
Publication of JP5922018B2 publication Critical patent/JP5922018B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2012522029A 2009-07-31 2010-07-30 Ｍｕｃ１抗体 Active JP5922018B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23021109P 2009-07-31 2009-07-31
EP09009942A EP2281844A1 (en) 2009-07-31 2009-07-31 MUC 1 antibodies
US61/230,211 2009-07-31
EP09009942.5 2009-07-31
PCT/EP2010/004663 WO2011012309A1 (en) 2009-07-31 2010-07-30 Muc1 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016000133A Division JP6272916B2 (ja) 2009-07-31 2016-01-04 Ｍｕｃ１抗体

Publications (3)

Publication Number Publication Date
JP2013500703A JP2013500703A (ja) 2013-01-10
JP2013500703A5 JP2013500703A5 (enExample) 2013-09-05
JP5922018B2 true JP5922018B2 (ja) 2016-05-24

Family

ID=41460131

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012522029A Active JP5922018B2 (ja) 2009-07-31 2010-07-30 Ｍｕｃ１抗体
JP2016000133A Active JP6272916B2 (ja) 2009-07-31 2016-01-04 Ｍｕｃ１抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016000133A Active JP6272916B2 (ja) 2009-07-31 2016-01-04 Ｍｕｃ１抗体

Country Status (17)

Country Link
US (1) US9217038B2 (enExample)
EP (3) EP2281844A1 (enExample)
JP (2) JP5922018B2 (enExample)
KR (1) KR101773506B1 (enExample)
CN (1) CN102574926B (enExample)
AR (1) AR077334A1 (enExample)
AU (1) AU2010278302B2 (enExample)
BR (1) BR112012002226A2 (enExample)
CA (1) CA2768888C (enExample)
CU (1) CU23972B1 (enExample)
EA (1) EA029954B1 (enExample)
IL (1) IL217827A (enExample)
MX (1) MX2012000874A (enExample)
NZ (1) NZ597563A (enExample)
SG (2) SG177527A1 (enExample)
WO (1) WO2011012309A1 (enExample)
ZA (1) ZA201200166B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2073842E (pt) 2006-09-10 2015-04-07 Glycotope Gmbh Utilização de células humanas provenientes de uma leucemia mielóide para expressão de anticorpos
EP1920782A1 (en) * 2006-11-10 2008-05-14 Glycotope Gmbh Carboyhdrate specific cellular immunity inducing microorganisms and fractions thereof
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
US8518405B2 (en) 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
JP6334166B2 (ja) 2010-08-10 2018-05-30 グリコトープ ゲーエムベーハー Ｆａｂグリコシル化抗体
US9845362B2 (en) 2010-10-08 2017-12-19 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
WO2013026887A1 (en) 2011-08-22 2013-02-28 Glycotope Gmbh Microorganisms carrying a tumor antigen
CN103848890B (zh) * 2012-11-30 2015-09-09 北京市结核病胸部肿瘤研究所 Muc1自身抗体识别的抗原多肽
EP2963126B1 (en) * 2013-03-01 2019-04-03 Saitama Medical University Method for evaluating side-effect onset risk in anticancer drug treatment, including detecting muc4 gene polymorphism
US10208125B2 (en) * 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
EP3127919A4 (en) * 2014-02-06 2017-08-16 Medicinal Chemistry Pharmaceuticals Co., Ltd. Antibody against mucin 4 (muc 4) glycopeptide and use therefor
CA2947404C (en) * 2014-04-28 2023-05-16 Medicinal Chemistry Pharmaceuticals, Co., Ltd. Anti-muc1 antibody or antigen-binding fragment thereof and uses thereof
WO2016026143A1 (en) * 2014-08-22 2016-02-25 Huiru Wang Saccharide-based biomarkers and therapeutics
US11554181B2 (en) 2014-09-05 2023-01-17 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
WO2016130726A1 (en) * 2015-02-10 2016-08-18 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
WO2017139975A1 (en) 2016-02-19 2017-08-24 Huiru Wang Antibodies against n-acetylglucosamine and n-acetyl-galactosamine
EP3543337B1 (en) 2016-11-18 2022-04-20 Astellas Pharma Inc. Novel anti-human muc1 antibody fab fragment
EP3570881A4 (en) * 2017-01-18 2020-08-19 Nanocruise Pharmaceutical Ltd. MONOCLONAL AND HUMANIZED ANTIBODIES DIRECTED AGAINST CANCER GLYCOPEPTIDE
EP3574015A1 (en) * 2017-01-27 2019-12-04 Glycotope GmbH Anti-cancer treatments with an anti-muc1 antibody and an erbb inhibitor
JP2020511959A (ja) 2017-03-29 2020-04-23 グリコトープ ゲーエムベーハー ヒト化抗ｃｄ４０抗体
CA3057758A1 (en) * 2017-03-29 2018-10-04 Glycotope Gmbh Pd-l1 and ta-muc1 antibodies
CA3055438A1 (en) * 2017-03-29 2018-10-04 Glycotope Gmbh Multispecific antibody constructs binding to muc1 and cd3
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
CN117003875A (zh) 2017-09-29 2023-11-07 第一三共株式会社 抗体或其功能性片段、多核苷酸、表达载体、宿主细胞、糖链重构抗体、药物组合物、应用
US11161911B2 (en) 2017-10-23 2021-11-02 Go Therapeutics, Inc. Anti-glyco-MUC1 antibodies and their uses
EP3700936A4 (en) * 2017-10-24 2021-05-26 Go Therapeutics, Inc. ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES
CN111819203A (zh) * 2018-03-01 2020-10-23 葛莱高托普有限公司 包含抗muc1抗体和il-15的融合蛋白构建体
WO2019221269A1 (ja) * 2018-05-17 2019-11-21 アステラス製薬株式会社 抗ヒトＭＵＣ１抗体Ｆａｂフラグメント、ペプチドリンカー及び／又は配位子を含む複合体
SG11202010496WA (en) 2018-05-18 2020-12-30 Daiichi Sankyo Co Ltd Anti-muc1 antibody-drug conjugate
CN108982854B (zh) * 2018-06-19 2021-07-27 哈尔滨医科大学 蛋白质muc13在制备诊断肝内胆管癌的试剂中的应用
EP3814384A4 (en) * 2018-06-29 2022-03-23 Go Therapeutics, Inc. ANTI-GLYC0-MUC1 ANTIBODIES AND THEIR USES
CN112839683B (zh) 2018-10-10 2023-11-14 安斯泰来制药株式会社 含有标记部-抗人抗体Fab片段复合物的药物组合物
TWI856078B (zh) 2019-03-25 2024-09-21 日商第一三共股份有限公司 抗體–吡咯并苯二氮呯衍生物結合物、其製造方法及其用途
CA3139180A1 (en) 2019-03-27 2020-10-01 Daiichi Sankyo Company, Limited Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor
CN118475617A (zh) * 2021-12-21 2024-08-09 美勒斯公司 针对与癌症相关的muc1的结合域
WO2023240135A2 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates
TW202506190A (zh) 2023-04-05 2025-02-16 日商第一三共股份有限公司 利用抗ｍｕｃ１抗體－藥物結合物投予的藥劑低敏感性癌之治療方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5683674A (en) 1987-01-07 1997-11-04 Imperial Cancer Research Technology Ltd. Antibody against human mucin core protein and method of preparing and using same
DE69329643T2 (de) 1992-04-13 2001-03-01 Dana-Farber Cancer Institute, Inc. Gegen karzinom-assoziierte antigene gerichtete antikörper
US5804187A (en) 1992-11-16 1998-09-08 Cancer Research Fund Of Contra Costa Modified antibodies with human milk fat globule specificity
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6465220B1 (en) 1998-12-21 2002-10-15 Glycozym Aps Glycosylation using GalNac-T4 transferase
US7147850B2 (en) 1999-08-18 2006-12-12 Altarex Medical Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
ATE290879T1 (de) 1999-08-18 2005-04-15 Altarex Medical Corp Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung
GB0029360D0 (en) 2000-12-01 2001-01-17 Univ Nottingham Humanised antibodies and uses thereof
PT1529060E (pt) 2002-07-22 2014-11-28 Glycotope Gmbh Processo para a produção de uma mucina imuno-estimuladora (muc1)
SI1530628T1 (sl) 2002-08-16 2011-02-28 Glycotope Gmbh Postopek za proizvodnjo s temperaturo induciranih lizatov tumorskih celic za uporabo kot imunogenske spojine
DE10303664A1 (de) 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
PT1654353E (pt) 2003-08-18 2013-08-23 Glycotope Gmbh Linhas de células tumorais nm f9 (dsm acc2606) e nm d4 (dsm acc2605), suas utilizações
JP4913604B2 (ja) 2004-02-13 2012-04-11 グリコトープ ゲーエムベーハー 高活性糖タンパク質−製造条件、及びその効率的製造方法
PT2073842E (pt) 2006-09-10 2015-04-07 Glycotope Gmbh Utilização de células humanas provenientes de uma leucemia mielóide para expressão de anticorpos
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies

Also Published As

Publication number Publication date
AR077334A1 (es) 2011-08-17
US9217038B2 (en) 2015-12-22
WO2011012309A8 (en) 2011-04-07
ZA201200166B (en) 2013-03-27
AU2010278302A1 (en) 2012-02-09
JP2013500703A (ja) 2013-01-10
JP2016041771A (ja) 2016-03-31
JP6272916B2 (ja) 2018-01-31
IL217827A (en) 2017-05-29
CN102574926A (zh) 2012-07-11
EA201270207A1 (ru) 2012-07-30
EP3421497A1 (en) 2019-01-02
SG177527A1 (en) 2012-02-28
IL217827A0 (en) 2012-03-29
WO2011012309A1 (en) 2011-02-03
EP2459595A1 (en) 2012-06-06
US20120128676A1 (en) 2012-05-24
BR112012002226A2 (pt) 2016-11-08
EP2281844A1 (en) 2011-02-09
AU2010278302B2 (en) 2014-12-18
EA029954B1 (ru) 2018-06-29
CU23972B1 (es) 2013-12-27
CN102574926B (zh) 2014-10-15
CA2768888A1 (en) 2011-02-03
KR101773506B1 (ko) 2017-08-31
MX2012000874A (es) 2012-02-01
SG10201404019XA (en) 2014-09-26
NZ597563A (en) 2013-08-30
CA2768888C (en) 2019-02-26
CU20120019A7 (es) 2012-06-21
KR20120051724A (ko) 2012-05-22

Similar Documents

Publication Publication Date Title
JP6272916B2 (ja) Ｍｕｃ１抗体
KR101782487B1 (ko) 신규 항-메소텔린 항체 및 이를 포함하는 조성물
AU2001249760B2 (en) Mucin-1 specific binding members and methods of use thereof
TWI777056B (zh) 結合至ssea4的單株抗體及其用途
EP4083072A1 (en) Muc1* antibodies
EP4289862A1 (en) Anti-human b7-h3 antibody and application thereof
CN103025760A (zh) 人源化egfr抗体
WO2018166507A1 (zh) 新型重组双功能融合蛋白及其制备方法和用途
JP2022527761A (ja) がん治療のための多重特異性作用物質
CN114786720B (zh) TriAx抗体的组合物及其制备和使用方法
JP7313730B2 (ja) エンドセリン受容体ａ結合力が向上した抗体
US9051370B2 (en) Humanized EGFR antibodies
TW201945033A (zh) 抗糖皮質激素誘導的腫瘤壞死因子受體（ｇｉｔｒ）的小型化抗體、其聚合物及應用
CN116284408A (zh) 结合人muc17的抗体、其制备方法及用途
JP2025523455A (ja) 腫瘍抗原に対するヒト化抗体又はその機能的断片
TW202323285A (zh) 抗cldn18.2抗體及其用途
CN117843793B (zh) 抗间皮素抗体、抗原结合片段及其用途
HK40082756A (en) Muc1* antibodies
JP2024544961A (ja) 抗ｃｌｄｎ１８．２モノクローナル抗体およびその使用
CN118165119A (zh) 包含IL-15/IL-15Rα复合物的重组蛋白及其用途
HK40054516B (zh) 新的间皮素抗体和包含其的组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130716

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150302

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160104

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160112

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160315

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160413

R150 Certificate of patent or registration of utility model

Ref document number: 5922018

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350